Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
30th Annual Meeting of the ISCP
Author(s): Daryl Dakay , Marion Patricio Added: 2 months ago

Prevention & Chronic Conditions

Heart Failure
Author(s): Apisara Lohachatinante , Nuttanun Kittikunkanyakit , Sayamon Sukkha , et al Added: 1 year ago

Anticoagulation
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 3 months ago

Heart Failure
EASD 24: Prespecified Analysis from the SELECT Trial
Author(s): Helen Colhoun Added: 1 year ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Job title: Director
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 1 year ago

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Carmen de la Hoz Lopez-Collado , María Laura García , Victoria Luis , et al Added: 2 months ago

Prevention & Chronic Conditions

Heart Failure
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 1 year ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 1 year ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure